bosentan anhydrous has been researched along with Diabetic Nephropathies in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, J; Dong, B; Huang, Y; Lv, W; Wang, YG; Zhou, Y | 1 |
| Alicic, RZ; Tuttle, KR | 1 |
| Böhm, F; Brismar, K; Gonon, A; Pernow, J; Rafnsson, A; Settergren, M | 1 |
| Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W | 1 |
| Clozel, M; Ding, SS; Hess, P; Qiu, C; Xi, JF; Zheng, N | 1 |
| Bellini, G; Bernobich, E; Borri, A; Cosenzi, A; Milutinovic, N; Trevisan, R | 1 |
| Chakrabarti, S; Chen, S; Cukiernik, M; Deng, D; Evans, T | 1 |
2 review(s) available for bosentan anhydrous and Diabetic Nephropathies
| Article | Year |
|---|---|
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Albuminuria; Atrasentan; Bosentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antioxidants; Bosentan; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelins; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Indoles; Janus Kinases; Maleimides; Polyamines; Protein Kinase C; Pyridones; Pyridoxamine; Sevelamer; Sulfonamides | 2014 |
1 trial(s) available for bosentan anhydrous and Diabetic Nephropathies
| Article | Year |
|---|---|
The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
Topics: Aged; Albuminuria; Antihypertensive Agents; Bosentan; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Humans; Hyperemia; Male; Microvessels; Middle Aged; Peripheral Vascular Diseases; Severity of Illness Index; Sulfonamides; Vasodilation | 2012 |
4 other study(ies) available for bosentan anhydrous and Diabetic Nephropathies
| Article | Year |
|---|---|
Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Topics: Amlodipine; Angiotensin II; Animals; Bosentan; Calcium Channel Blockers; Collagen Type IV; Diabetic Nephropathies; Drug Therapy, Combination; Endothelin Receptor Antagonists; Hypertension; Kidney; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sulfonamides; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |
Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bosentan; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Endothelin A Receptor Antagonists; Glomerular Filtration Rate; Kidney; Male; Organ Size; Rats; Rats, Wistar; Sulfonamides; Vasoconstriction | 2003 |
Nephroprotective effect of bosentan in diabetic rats.
Topics: Animals; Blood Glucose; Bosentan; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Fibronectins; Kidney; Rats; Rats, Inbred WKY; Sulfonamides; Transforming Growth Factor beta | 2003 |
Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins.
Topics: Animals; Antihypertensive Agents; Basement Membrane; Bosentan; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Endothelins; Fibronectins; Galactose; Humans; Kidney; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides | 2002 |